

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re PATENT APPLICATION OF

KAWASHIMA et al

Atty. Ref.: 1430-268

Serial No.: 09/402,260

Group Art Unit: 1655

Filed: September 30, 1999

Examiner: Wilder, C.

For: METHOD OF NUCLEIC ACID SEQUENCING

* * * * *

October 16, 2001

SUBMISSION

Hon. Commissioner of Patents
and Trademarks
Washington, DC 20231

Sir:

Submitted herewith is an executed Exclusive Substitute
Power of Attorney relating to the above.

Kindly direct all future correspondence regarding this
matter to:

Mary J. Wilson
NIXON & VANDERHYE P.C.
1100 North Glebe Road
8th Floor
Arlington, Virginia 22201-4714.

Respectfully submitted,

NIXON & VANDERHYE, P.C.

By Mary J. Wilson
Mary J. Wilson
Reg. No. 32,955


MJW:tat

1100 North Glebe Road
8th Floor
Arlington, Virginia 22201-4714
Telephone: (703) 816-4000
Facsimile: (703) 816-4100

567833

RECEIVED
OCT 17 2001
TECH CENTER 1600/2900
[Signature]





RECEIVED
OCT 17 2001
TECH CENTER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of

KAWASHIMA et al

Serial No. 09/402,260

Filed: September 30, 1999

For: METHOD OF NUCLEIC ACID SEQUENCING

Atty. Ref.: 1430-268

Group: 1655

Examiner: Wilder, C.

* * * * *

Assistant Commissioner for Patents
Washington, DC 20231

Sir:

**EXCLUSIVE SUBSTITUTE POWER OF ATTORNEY
AND EXCLUSIVE PROSECUTION HEREAFTER BY
ASSIGNEE UNDER 37 C.F.R. §§ 1.36, 3.71 AND 3.73**

SmithKline Beecham Corporation, being the owner of all right, title and interest in the above-identified patent application, hereby revokes all previous powers of attorney in this case, if any, and hereby appoints Nixon & Vanderhye, P.C., 1100 North Glebe Rd., 8th Floor, Arlington, Virginia 22201-4714, telephone number (703) 816-4000, facsimile number (703) 816-4100, and the following attorneys thereof (of the same address) individually and collectively its attorneys to prosecute this application and to transact all business in the Patent and Trademark Office in connection therewith, and with the resulting patent: Larry S. Nixon, 25640; Arthur R. Crawford, 25327; James T. Hosmer, 30184; Robert W. Faris, 31352; Richard G. Besha, 22770; Mark E. Nusbaum, 32348; Michael J. Keenan, 32106; Bryan H. Davidson, 30251; Stanley C. Spooner, 27393;

Leonard C. Mitchard, 29009; Duane M. Byers, 33363; Jeffry H. Nelson, 30481; John R. Lastova, 33149; H. Warren Burnam, Jr. 29366; Mary J. Wilson, 32955; J. Scott Davidson, 33489; Alan M. Kagen, 36178; Robert A. Molan, 29834; B. J. Sadoff, 36663; James D. Berquist, 34776; Updeep S. Gill, 37334; Michael J. Shea, 34725; Donald L. Jackson, 41090; Michelle N. Lester, 32331; Frank P. Presta, 19828; Joseph S. Presta, 35329; Joseph A. Rhoa, 37515; Raymond Y. Mah, 41426; Chris Comuntzis, 31097.

SmithKline Beecham Corporation also authorizes Nixon & Vanderhye to delete any attorney names/numbers no longer with the firm and to act and rely solely on instructions communicated from the person, attorney, firm or other organization sending instructions to Nixon & Vanderhye on behalf of the owner.

Certificate Under 37 C.F.R. §3.73(b)

SmithKline Beecham Corporation, a corporation organized under the laws of the State of Pennsylvania, having its principal place of business at One Franklin Plaza, P.O. Box 7929, Philadelphia, Pennsylvania 19101-7929, states that it is the assignee of the entire right, title and interest in the patent application identified above by virtue of an assignment from GLAXO GROUP LIMITED to the aforesaid assignee, a copy of the assignment being attached.

The undersigned (whose title is typed below) is empowered to sign this statement on behalf of SmithKline Beecham Corporation.

KAWASHIMA et al
Serial No. 09/402,260

SmithKline Beecham Corporation

22nd June 2001 By: [Signature]
Date Name: PETER JOHN GIDDINGS
Title: BY ITS ATTORNEY

ASSIGNMENT OF PATENT APPLICATION

SOLE

WHEREAS, Glaxo Group Limited, located at Glaxo Wellcome House, Berkeley Avenue, Greenford, Middlesex, UB6 0NN, United Kingdom, hereinafter referred to as "Assignor," is the current owner of the below-identified application for United States Letters Patent:

Title of Invention: METHOD OF NUCLEIC ACID SEQUENCING

Filing Date: September 30, 1999

Application No.: 09/402,260:

Previous Assignment: Recorded: 2/27/2000; Reel/Frame: 010611/0411; and

SmithKline Beecham Corporation

One Franklin Plaza, PO Box 7929, Philadelphia 19101-7929

WHEREAS, ~~Glaxo Wellcome Inc.~~, located at ~~Five Moore Drive, Research Triangle Park, NC.~~

~~27709~~, hereinafter referred to as "ASSIGNEE," is desirous of acquiring an interest in the application and in any U.S. Letters Patent and Registrations which may be granted on the same;


For good and valuable consideration, receipt of which is hereby acknowledged by Assignor, Assignor has assigned, and by these presents does assign to Assignee all right, title and interest in and to the application, and in and to any Letters Patent and Registrations which may hereafter be granted on any patent application claiming priority from the same in the United States. The right, title and interest is to be held and enjoyed by Assignee and Assignee's successors and assigns as fully and exclusively as it would have been held and enjoyed by Assignor had this Assignment not been made, for the full term of any Letters Patent and Registrations which may be granted thereon, or of any division, renewal, continuation in whole or in part, substitution, conversion, reissue, prolongation or extension thereof.

Assignor further agrees that Assignor will, without charge to Assignee, but at Assignee's expense, (a) cooperate with Assignee in the prosecution of U.S. Patent application, (b) execute, verify, acknowledge and deliver all such further papers, including applications and instruments of transfer, and (c) perform such other acts as Assignee lawfully may request to obtain or maintain Letters Patent and Registrations for the invention and improvements in any and all countries, and to vest title thereto in Assignee, or Assignee's successors and assigns.

IN TESTIMONY WHEREOF, Assignor has signed his/her name on the date indicated.

Name of Person Signing: Wendy A. Filler

Title of Person Signing: By Its Attorney
Glaxo Group Limited

Signature: 

Date: 10/4/01